Browse the evidence

Obesity is a major public health problem with a prevalence increasing at an alarming rate worldwide.

Health practitioners should prioritize addressing obesity as a critical public health issue.

The effectiveness of currently approved anti-obesity drugs and other therapeutic avenues is reviewed.

Healthcare providers should stay informed about the effectiveness of anti-obesity medications.

Semaglutide improved hemoglobin A1c levels and reduced glycemic variability without increasing hypoglycemia.

Semaglutide may enhance glycemic control in type 1 diabetes patients.

Several agencies have approved tirzepatide for the treatment of type 2 diabetes and obesity.

Tirzepatide is a viable treatment option that is recognized by regulatory agencies for managing type 2 diabetes and obesity.

Tirzepatide has potential cardiovascular benefits.

Practitioners should consider the cardiovascular implications when prescribing TZP.

Brown adipose tissue (BAT) is identified as a thermogenic organ in human adults, which may be targeted for obesity and cardiometabolic disease treatment.

Activating BAT could be a novel strategy for treating obesity and related diseases.

Integrating shared decision-making (SDM) into obesity management enhances patient-centered care and has the potential to improve long-term outcomes.

Practitioners should consider incorporating SDM to enhance patient engagement and outcomes in obesity care.

Programs incorporating SDM reported improved patient engagement, satisfaction, and health outcomes across diverse demographic groups.

Incorporating SDM can lead to better patient experiences and outcomes in obesity management.

Common facilitators of SDM success include the use of decision aids, culturally tailored counseling, and multidisciplinary team involvement.

Healthcare providers should utilize decision aids and culturally tailored approaches to enhance SDM in obesity care.

Long-term intake of UPFs leads to addiction due to additives including fat, caffeine, and sugar.

Health professionals should consider the addictive potential of UPFs when advising clients.

Significant improvements were observed across quality-of-life scores.

Incorporating exercise and nutrition can enhance the quality of life for breast cancer patients.

Distant teams lost similar amounts of weight in all 3 arms but did not keep it off during maintenance.

Interventions may need to address long-term maintenance strategies for participants like Distant teams.

Delaying breakfast from 0700 h to 0930 h or 1200 h reduces postprandial glycaemia.

Practitioners can recommend delaying breakfast to improve glycaemic control in patients with type 2 diabetes.

Non-genetic factors are involved in determining body weight and body composition.

Practitioners should consider non-genetic factors when addressing body weight and composition.

Human eating behavior is a learned habitual behavior influenced by past experiences.

Understanding that eating habits are learned can help practitioners develop better interventions.

The metabolic phenotype can be modified and affects the fate of ingested energy.

Practitioners should recognize that metabolic adaptations can influence weight management strategies.

Controlling the activities of inflammatory mediators can reduce the incidence of chronic diseases.

Diet, exercise, and lifestyle choices should focus on managing inflammation.

Human obesity is associated with insulin resistance and results in metabolic abnormalities and cardiovascular complications.

Practitioners should be aware of the metabolic and cardiovascular risks associated with obesity.

Associations between obesity and health are likely causal.

Understanding that obesity has likely causal links to health can guide interventions.

Incretin mimetics have a positive impact on related comorbidities, such as sleep apnea and heart failure.

Practitioners should be aware of the broader health benefits of incretin mimetics beyond glucose control.

Patients may benefit from education on proper drug administration, anticipated adverse effects, and nutrition considerations with treatment.

Educating patients on these aspects can improve treatment adherence and outcomes.

Durable LVAD patients treated with GLP-1 RA had a significant weight reduction from 116 kg to 110 kg (p-value < 0.001).

GLP-1 RA may be effective for weight management in LVAD patients.

GLP-1 RA therapy improved HBA1C levels from 6.4 to 5.7 (p-value 0.003) in LVAD patients.

GLP-1 RA may help improve glycemic control in LVAD patients.

White rice intake is associated with a 18% increased risk of type 2 diabetes mellitus (T2DM) when comparing the highest with the lowest category of intake.

Practitioners should consider the potential increased risk of T2DM when advising on white rice consumption.